Florida Hospital Waterman Cancer Institute among the first to offer break-through prostate cancer treatment.
New treatment helping men with prostate cancer live longer now available
Florida Hospital Waterman Cancer Institute among the first to offer break-through treatment
TAVARES, Fla. (Sept. 17, 2013) – A new treatment is giving men with advanced prostate cancer new hope, and Florida Hospital Waterman Cancer Institute is among the first centers in Central Florida to provide the ground-breaking therapy.
Xofigo® (Radium-223 dichloride) was recently approved by the Food and Drug Administration (FDA) for the treatment of patients with metastatic castration-resistant prostate cancer that has spread to the bones, but no other organs. In a study released in the New England Journal of Medicine earlier this year, the treatment proved effective during trials, extending the life of patients by three and a half months on average.
“Prior to this new treatment, there have been very few options for patients with metastatic castration-resistant prostate cancer,” said Jeffrey Brabham, M.D., Radiation Oncologist at the Florida Hospital Waterman Cancer Institute. “At this stage, many patients are too weak to undergo traditional chemotherapy. This new treatment, administered through injection, directly targets the cancer in the bone while sparing surrounding healthy tissue and bone marrow. It is an excellent new option for this patient population.”
According the American Cancer Society, about 30,000 U.S. men die from prostate cancer each year, often from cancer that has spread to the bone.
“In addition to extending the lives of patients in the clinical trial, the treatment was also found to reduce bone pain and improve patients’ quality of life,” Dr. Brabham said. “While there have been similar treatments available in the past, this is the first commercially available alpha particle emitter. This category of radiation particle spares more bone marrow and thus preserves blood cell production much better than previous therapies, which used beta particle emitters.”
According the Dr. Brabham, Xofigo is administered as an intravenous injection once a month for six months. His patient was among the first in Central Florida to receive the treatment after FDA approval. “We are committed to providing advanced cancer treatment to the patients of Lake County and this region,” Dr. Brabham said. “By being on the cutting-edge of new treatment options such as Xofigo, we are not only helping to extend the lives of our patients, but also helping to improve their overall quality of life.”
About Florida Hospital Waterman Cancer Insitute
Florida Hospital Waterman Cancer Institute is a comprehensive community cancer program dedicated to providing the most advanced treatment and care available to cancer patients in Lake County and Central Florida.
The Institute offers radiation oncology and medical oncology services as well as a team of board certified surgeons and the only fellowship-trained surgical oncologist in Lake County. The Florida Hospital Waterman Institute also features a Cancer Resource Library and support services for patients and their families, all available at no charge and open to the public.
About Florida Hospital Waterman
Florida Hospital Waterman is a 269-bed, full-service community hospital located in the heart of Lake County. Founded in 1938 by Frank Waterman, president of the Waterman Fountain Pen Company, the hospital has grown from an 18-bed facility to a leading provider of acute and home health services in Central Florida. The hospital joined the Adventist Health System in 1992, and moved to its current location in 2003. With more than 1,500 employees and nearly 280 physicians on its medical staff, the hospital treats more than 14,000 inpatients a year and treats nearly 50,000 patients in its Emergency Department annually.